Saturday 02 Mar, 2024 10:56 PM
Site map | Locate Us | Login
   Welspun Corp gains after arm plans to set up manufacturing facility in Madhya Pradesh    CRISIL revises outlook on ratings of Angel One to 'Positive?    Patel Engg JV bags LoA for Rs 525-cr order    H.G. Infra rises on bagging Rs 447-cr LoA    Vimta Labs climbs on securing Govt grant for upgrading lab    Swan Energy Ltd leads losers in 'A' group    Gensol Engineering Ltd leads losers in 'B' group    Volumes jump at Rallis India Ltd counter    Banking stocks slide    RBL Bank Ltd soars 1.5%, up for third straight session    Canara Bank gains for third straight session    JSW Steel Ltd up for third straight session    NMDC Ltd spurts 1.58%    Jindal Steel & Power Ltd gains for third straight session    National Aluminium Company Ltd gains for third straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Jubilant Ingrevia Q3 PAT slides 29% YoY to Rs 92 cr
31-Jan-23   15:18 Hrs IST

Profit before tax slipped 34.93% to Rs 121.60 crore in Q3 FY23 compared with Rs 186.87 crore in Q3 FY22.

EBITDA declined 29% to Rs 158 crore in Q3 FY23 as against Rs 222 crore in Q3 FY22. EBITDA margin stood at 13.7% in Q3 FY23 compared with 17.3% in corresponding quarter last year.

Overall revenue is 10% lower on YoY basis, mainly on account of lower sales performance of nutrition & health solution business, while volumes in specialty chemicals products and acetic anhydride continue to improve.

Revenue from specialty chemicals grew by 34% YoY to Rs 468 crore in Q3 FY23, driven by higher price realization and volume growth across product segments. Share of revenue to customers having agro chemical end use has shown significant growth.

Revenue from nutrition business de-grew YoY by 39% to Rs 132 crore in Q3 FY23, on account of lower demand, due to prolonged impact of bird and swine flu in EU and US regions, leading to lower realization.

Revenue from chemical intermediates de-grew by 23% on YoY to Rs 559 crore in Q3 FY23, mainly driven by lower price of feed stock (ie Acetic Acid) leading to lower realization of finished products i.e. Acetic Anhydride & Ethyl Acetate. The company has further improved its market share and volumes of Acetic Anhydride in EU region on YoY.

“Specialty Chemicals segment would continue to grow. Overall our FY23, full year performance is expected to remain in line with our last three quarters. We are fully committed towards our growth aspirations and we are excited to realise the emerging opportunities through our ongoing Growth Capex plan, which we have now improved from earlier Rs 2,050 crore to now Rs 2,275 crore during FY22 to FY25 Period. We continue our efforts towards improving our revenue mix of specialty and nutrition segments to 65% by FY27 from 44% in FY22 and we believe this to be a key driver for overall EBIDTA and Margin improvements,” the company stated in exchange filing.

The board of directors declared interim dividend of Rs 2.50 per equity share. The record date for the same is fixed on 10 February 2023.

Shyam S Bhartia, chairman and Hari S Bhartia, co-chairman, Jubilant Ingrevia said, We are pleased to inform that our Specialty Chemicals Business revenue grew by 34% YoY and absolute EBIDTA grew by 15% YoY driven by higher volumes and improved price realization.

In Nutrition & Health Solution business the demand of Niacinamide (Vitamin B3) continue to be subdued impacting our price realization though we have improved our volumes sequentially. The demand related challenges of Vitamin B3 are short-term and we continue to remain focused towards improving our presence in food and cosmetics segment. In chemical intermediates business the revenue on YoY basis is impacted due to lower prices of feed stock (Acetic Acid), leading to lower sales prices of Acetic Anhydride and Ethyl Acetate.

The company has firm plans to significantly reduce overall energy cost in phased manner through various initiatives by sourcing power from Grid and renewable sources, optimizing coal consumption through efficiency improvement in consumption as well as in generation. We continue to focus on our growth plans through new products and platforms and we are committed to deliver robust growth in the future.

Jubilant Ingrevia is a global integrated life science products and innovative solutions provider serving, pharmaceutical, nutrition, agrochemical, consumer and industrial customers with its customised products and solutions that are innovative, cost effective and conforming to premium quality standards. The company is engaged in manufacturing and supply of speciality chemicals, nutrition & health solutions and chemical intermediates through five manufacturing facilities in India.

The scrip surged 4.25% to Rs 493 on the BSE.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 31073882
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd